Novobiocin Sodium

Phase 1Biologic

Novobiocin Sodium is one of 10 biologic programs targeting Metastatic Malignant Solid Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Malignant Solid NeoplasmRecruiting

Metastatic Malignant Solid NeoplasmPhase 1

Recruiting

Competition

Competitive Landscape

11 competitors in Metastatic Malignant Solid Neoplasm

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

2 2

Taxol

Teva

Phase 2

1 3

Tasigna

AAzurity Pharmaceuticals

Phase 2

1 4

Herceptin

Roche

Phase 1

2 5

Keytruda

Merck & Co.

Phase 1

1 6

Hycamtin

MMeitheal

Preclinical

1 7

Veliparib

AbbVie

Preclinical

1 8

Pidnarulex

NNational Cancer Institute (NCI)

Phase 1

1 9

Edodekin Alfa

NNational Cancer Institute (NCI)

Phase 1

1 10

Novobiocin Sodium

NNational Cancer Institute (NCI)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Metastatic Malignant Solid Neoplasm

NCT05687110

Clinical

Trials by Indication[1]

Metastatic Malignant Solid Neoplasm1 trial

A Phase 1 Study of the Polymerase Theta (POLθ) Inhibitor Novobiocin in BRCA- Mutant and Other DNA Damage Repair-Deficient Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05687110·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Novobiocin Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Novobiocin Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Novobiocin Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

Novobiocin Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Metastatic Malignant Solid Neoplasm1 trial

References

Drug Info

Quick Facts

Related News